The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25
: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .
: £12.9 million (+27.4%), supported by synthetic biology.
